Addressing Unmet Medical Needs
Late-stage drug candidates developed by Edesa Biotech aim to help patients with limited treatment options for inflammatory and immune-related diseases
Edesa Biotech is a clinical-stage biopharmaceutical company founded by experts in the fields of inflammation, infectious disease and gastroenterology. We are exploring new ways to treat these diseases, including alternatives to topical steroids, which can have serious side-effects. This innovative approach is made possible by proprietary technologies developed to inhibit the inflammatory process or modulate the body’s immune response.
Our most advanced drug candidate is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure.
We are also developing product candidates for a number of chronic dermatological and inflammatory conditions, including:
- Allergic Contact Dermatitis (ACD), a common occupational and work-related skin condition;
- Vitiligo, an autoimmune disorder that causes the skin to lose its color in patches; and
- Systemic Sclerosis (SSc), an autoimmune rheumatic disorder that causes scarring and hardening of skin and internal organs.
At the heart of Edesa’s corporate culture is an entrepreneurial spirit, and we are always building. See our latest news releases for updates on these clinical programs and more.
– Par Nijhawan, MD, Chief Executive Officer
Our leadership has years of specialized expertise spanning pharmaceutical drug development, biotech research and medical care.
Online Contact Form
Our executive offices are located just outside Toronto, Ontario.
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario L3R 5H6
+1 289.800.9600 (Canada)
+1 805.488.2800 (USA)
Join us in the discovery and development of a new generation of pharmaceutical drugs